Skip to main content
. 2016 Feb 26;3(2):e207. doi: 10.1212/NXI.0000000000000207

Figure 3. Impressively rapid changes in seizure frequency and memory performance.

Figure 3

Seizures in patients with (A) leucine-rich glioma inactivated protein 1 (LGI1) antibodies and (B) contactin-associated protein-2 (CASPR2) antibodies. The antiepileptic drug defined daily dose (AED DDD) figures show that this was not due to anticonvulsive therapy. (C) Memory performance of anti–NMDA receptor (NMDAR) patients with 2 patients improving by >1 SD already at early follow-up (red arrows). Note the preservation of hippocampal volume in patient LGI1-B in contrast to the hippocampal sclerosis that was present from the beginning of IA in patient LGI1-C. This is a possible explanation for his incomplete response. *Seizure-free. †Value 0. #No data. AED DDD according to WHO (http://www.whocc.no/atc_ddd_index/; accessed September 2, 2015).